PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Clinical trials for PULMONARY ALVEOLAR PROTEINOSIS (PAP) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ALVEOLAR PROTEINOSIS (PAP) trials appear
Sign up with your email to follow new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets rogue immune cells in rare diseases
Disease control CompletedThis early-phase study tested whether rituximab, a drug that targets certain white blood cells, is safe for people with rare diseases where the body's immune system attacks its own proteins. Seven adults with conditions like pulmonary alveolar proteinosis or severe candidiasis re…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Scientists investigate why lung cells fail to clean in rare genetic disease
Knowledge-focused CompletedThis study looked at a rare lung condition called pulmonary alveolar proteinosis (PAP) caused by changes in the MARS gene. Researchers wanted to understand why lung cleaning cells (macrophages) cannot remove fatty buildup in the lungs. They studied cells from 20 children with and…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 17, 2026 06:51 UTC